Exelixis | EXEL - Dochód Netto





Dochód Netto Zmiana Data
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Amgen USD 1.82B 486M 2026-03
AstraZeneca USD 3.08B 754M 2026-03
Bayer EUR 2.76B 6.52B 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Cytokinetics USD -206.03M 23M 2026-03
Eisai JPY -3.25B 20.43B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Exelixis USD 210.47M 34.06M 2026-03
Genmab DKK 31M 370M 2025-12
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
MacroGenics USD -14.16M 30.98M 2025-12
Merck USD -4.24B 7.2B 2026-03
Moderna USD -1.34B 517M 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Novartis USD 3.16B 747M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR -801M 3.6B 2025-12
Takeda JPY -24.32B 127.96B 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Xencor USD -128.92M 122.26M 2026-03